GB2456237B8 - Stable adenosine receptor mutants - Google Patents

Stable adenosine receptor mutants

Info

Publication number
GB2456237B8
GB2456237B8 GB0901111A GB0901111A GB2456237B8 GB 2456237 B8 GB2456237 B8 GB 2456237B8 GB 0901111 A GB0901111 A GB 0901111A GB 0901111 A GB0901111 A GB 0901111A GB 2456237 B8 GB2456237 B8 GB 2456237B8
Authority
GB
United Kingdom
Prior art keywords
gpcr
ligand
mutants
binding
adenosine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB0901111A
Other languages
English (en)
Other versions
GB2456237B (en
GB0901111D0 (en
GB2456237A (en
Inventor
Antony Johannes Warne
Christopher Gordon Tate
Francesca Magnani
Malcolm Peter Weir
Maria Josefa Serrano-Vega
Richard Henderson
Yoko Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0705450A external-priority patent/GB0705450D0/en
Priority claimed from GB0724052A external-priority patent/GB0724052D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GB0901111A priority Critical patent/GB2456237B8/en
Publication of GB0901111D0 publication Critical patent/GB0901111D0/en
Publication of GB2456237A publication Critical patent/GB2456237A/en
Publication of GB2456237B publication Critical patent/GB2456237B/en
Application granted granted Critical
Publication of GB2456237B8 publication Critical patent/GB2456237B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
GB0901111A 2007-03-22 2008-03-20 Stable adenosine receptor mutants Active GB2456237B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0901111A GB2456237B8 (en) 2007-03-22 2008-03-20 Stable adenosine receptor mutants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0705450A GB0705450D0 (en) 2007-03-22 2007-03-22 Mutant proteins and method for selecting them
GB0724052A GB0724052D0 (en) 2007-12-08 2007-12-08 Mutant proteins and methods for selecting them
GB0805267A GB2447786C (en) 2007-03-22 2008-03-20 Mutant G-protein coupled receptor proteins and methods for selecting them
GB0901111A GB2456237B8 (en) 2007-03-22 2008-03-20 Stable adenosine receptor mutants

Publications (4)

Publication Number Publication Date
GB0901111D0 GB0901111D0 (en) 2009-03-11
GB2456237A GB2456237A (en) 2009-07-15
GB2456237B GB2456237B (en) 2009-10-28
GB2456237B8 true GB2456237B8 (en) 2009-12-09

Family

ID=39386585

Family Applications (4)

Application Number Title Priority Date Filing Date
GB0901111A Active GB2456237B8 (en) 2007-03-22 2008-03-20 Stable adenosine receptor mutants
GB0805267A Active GB2447786C (en) 2007-03-22 2008-03-20 Mutant G-protein coupled receptor proteins and methods for selecting them
GB0901110A Active GB2456236B8 (en) 2007-03-22 2008-03-20 Stable muscarinic receptor mutants
GB0901095A Active GB2456235B8 (en) 2007-03-22 2008-03-20 Stable beta-adrenergic receptor mutants

Family Applications After (3)

Application Number Title Priority Date Filing Date
GB0805267A Active GB2447786C (en) 2007-03-22 2008-03-20 Mutant G-protein coupled receptor proteins and methods for selecting them
GB0901110A Active GB2456236B8 (en) 2007-03-22 2008-03-20 Stable muscarinic receptor mutants
GB0901095A Active GB2456235B8 (en) 2007-03-22 2008-03-20 Stable beta-adrenergic receptor mutants

Country Status (14)

Country Link
US (7) US8785135B2 (enExample)
EP (4) EP2450445A1 (enExample)
JP (6) JP4842400B2 (enExample)
CN (2) CN103641908A (enExample)
AT (1) ATE544854T1 (enExample)
AU (1) AU2008228085B2 (enExample)
CA (1) CA2681415C (enExample)
DK (1) DK2121919T3 (enExample)
ES (2) ES2381780T3 (enExample)
GB (4) GB2456237B8 (enExample)
HR (1) HRP20120336T1 (enExample)
PL (1) PL2121919T3 (enExample)
PT (1) PT2121919E (enExample)
WO (1) WO2008114020A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120336T1 (hr) 2007-03-22 2012-05-31 Heptares Therapeutics Limited Receptori vezani na mutacije g-proteina i metode njihovog odabira
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) * 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
WO2012022928A2 (en) 2010-08-20 2012-02-23 Heptares Therapeutic Ltd Biological materials and uses thereof
US20140031525A1 (en) * 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP6263773B2 (ja) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質およびその調製および使用方法
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
US10458993B2 (en) 2012-06-01 2019-10-29 Heptares Therapeutics Limited Assay for assessing conformational stability of membrane protein
US9593157B2 (en) 2013-01-30 2017-03-14 Vib Vzw Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
WO2014140586A2 (en) 2013-03-15 2014-09-18 Medical Research Council Mutant proteins and methods for their production
US9670264B2 (en) 2013-04-25 2017-06-06 The Trustees Of The University Of Pennsylvania Water soluble G-protein coupled receptor
WO2014176524A2 (en) 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
WO2014198528A2 (en) * 2013-06-11 2014-12-18 Paul Scherrer Institut Method for determining mutateable ligand-gpcr binding at single amino acid resolution and pairs of mutated ligand and gpcr
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
CN104151401A (zh) * 2014-06-05 2014-11-19 维亚生物科技(上海)有限公司 融合表达离子通道蛋白及运输蛋白的方法及其使用的蛋白片断
GB2527286A (en) 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
EP3212784B1 (en) 2014-10-31 2019-05-29 Abilita Bio, Inc. Modified membrane spanning proteins and methods for the preparation and use thereof
CA3032514C (en) 2015-07-31 2021-05-04 Takehiro SHINODA Method of producing membrane protein and utilization thereof
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
EP3205450A1 (de) * 2016-02-09 2017-08-16 Hermes Schleifkörper GmbH Verfahren zur herstellung eines keramischen formkörpers
CN109415445A (zh) 2016-05-04 2019-03-01 阿比利塔生物公司 用于制备多跨膜蛋白的方法和平台
CN113501881B (zh) * 2017-09-27 2023-07-28 北京大学 融合蛋白
US12123814B1 (en) * 2019-06-14 2024-10-22 Pierce Biotechnology, Inc. G- protein coupled receptor extraction formulations
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
CN114038498B (zh) * 2022-01-06 2022-03-18 北京晶泰科技有限公司 Gpcr的热稳定性突变预测方法、结构筛选方法及其装置
CN120948816A (zh) * 2025-10-20 2025-11-14 国科大杭州高等研究院 一种g蛋白偶联受体的热稳定性突变位点筛选方法及其用途

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
JP3147916B2 (ja) 1991-03-08 2001-03-19 森永製菓株式会社 体外免疫方法
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
WO1993025677A1 (en) * 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
WO1995032425A1 (en) 1994-05-23 1995-11-30 Smithkline Beecham Corporation Encoded combinatorial libraries
US20020028443A1 (en) 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
WO1997035881A2 (en) 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
AU2728297A (en) 1996-04-15 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain G-protein-coupled receptor compositions and me thods
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
WO1999051777A2 (en) 1998-04-06 1999-10-14 Bunsen Rush Laboratories, Inc. Directed evolution biosensors
US6692696B1 (en) 1998-06-18 2004-02-17 ARETé ASSOCIATES Biosensor
EP1123391A2 (en) * 1998-09-01 2001-08-16 BASF Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US7094593B1 (en) 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
AU4847600A (en) 1999-05-14 2000-12-05 Repliscent, Inc. G-protein coupled receptor (gpcr) based biosensors and sense replication systems
AU782959B2 (en) * 1999-11-17 2005-09-15 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
CA2399593A1 (en) 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
US7678539B2 (en) 2000-08-10 2010-03-16 Corning Incorporated Arrays of biological membranes and methods and use thereof
WO2002018590A2 (en) 2000-08-30 2002-03-07 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6448377B1 (en) 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
CA2425149A1 (en) 2000-10-26 2002-08-01 New England Medical Center Hospitals, Inc. Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
US20030232331A1 (en) 2000-12-05 2003-12-18 Casman Stacie J. Novel proteins and nucleic acids encoding same
WO2002083736A2 (en) 2001-02-14 2002-10-24 Amgen, Inc. G-protein coupled receptor molecules and uses thereof
CA2439383A1 (en) 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US7208279B2 (en) 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
EP2369344B1 (en) 2001-03-30 2016-11-16 Suntory Holdings Limited Structural model of G protein-coupled receptor and method for designing ligand capable of binding to G protein-coupled receptor using the structural model
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US20050009204A1 (en) 2003-07-11 2005-01-13 Ye Fang Multiplexed binding assays for receptor arrays
US20030170842A1 (en) 2001-10-25 2003-09-11 Williams Pamela A. Crystals of cytochrome P450 2C9, structures thereof and their use
US7115377B2 (en) 2001-10-26 2006-10-03 Atto Bioscience, Inc. Cell-based assays for G-protein-coupled receptor-mediated activities
JP2004238384A (ja) * 2002-03-28 2004-08-26 Takeda Chem Ind Ltd 新規スクリーニング方法
US20060073516A1 (en) 2002-03-28 2006-04-06 Yasuaki Ito Novel screening method
JP4344928B2 (ja) * 2002-04-24 2009-10-14 萬有製薬株式会社 ヒスタミン受容体ｈ３常活性変異体およびその利用
ATE457728T1 (de) 2002-05-01 2010-03-15 Vertex Pharma Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
US20040096914A1 (en) 2002-11-20 2004-05-20 Ye Fang Substrates with stable surface chemistry for biological membrane arrays and methods for fabricating thereof
CA2525286C (en) * 2003-05-20 2012-09-11 The University Court Of The University Of Glasgow Materials and methods relating to g-protein coupled receptor oligomers
US7745161B2 (en) 2003-12-19 2010-06-29 Palo Alto Research Center Incorporated Amplification of enzymatic reactions for use with an enthalpy array
US20060281699A1 (en) 2004-05-12 2006-12-14 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
WO2006023248A2 (en) 2004-07-28 2006-03-02 The Trustees Of Columbia University In The City Of New York Processes for producing and crystallizing g-protein coupled receptors
JP2006340717A (ja) * 2005-05-11 2006-12-21 Sekisui Chem Co Ltd Ｇタンパク質共役型受容体に対する結合性評価方法及び評価用組成物、融合タンパク質、並びに、遺伝子
FR2890174B1 (fr) 2005-08-30 2009-04-24 Cis Bio Internat Sa Procede pour la mise en evidence d'un processus biologique par mesure d'un fret
US20070154947A1 (en) 2005-08-31 2007-07-05 The Trustees Of Princeton University Chemical biodiscriminator
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
US7495024B2 (en) * 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
HRP20120336T1 (hr) 2007-03-22 2012-05-31 Heptares Therapeutics Limited Receptori vezani na mutacije g-proteina i metode njihovog odabira
WO2009051769A1 (en) 2007-10-17 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for crystallizing g protein-coupled receptors
EP2203475B1 (en) 2007-10-22 2014-04-16 The Scripps Research Institute Methods and compostions for obtaining high-resolution crystals of membrane proteins
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
WO2012022928A2 (en) 2010-08-20 2012-02-23 Heptares Therapeutic Ltd Biological materials and uses thereof
US8470561B2 (en) 2010-08-30 2013-06-25 ConfometRX Inc. GPCR comprising an IC2 insertion
US20140031525A1 (en) 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
WO2012158555A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
WO2013142278A1 (en) 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
US10458993B2 (en) 2012-06-01 2019-10-29 Heptares Therapeutics Limited Assay for assessing conformational stability of membrane protein
WO2014028644A1 (en) 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
US20150261911A1 (en) 2014-03-13 2015-09-17 Heptares Therapeutics Limited Crystal structure

Also Published As

Publication number Publication date
JP2018164456A (ja) 2018-10-25
GB2456236B (en) 2009-10-28
GB2456237B (en) 2009-10-28
GB2447786B (en) 2009-11-11
WO2008114020A3 (en) 2009-03-19
ATE544854T1 (de) 2012-02-15
EP2121919A2 (en) 2009-11-25
GB2456235B8 (en) 2009-12-09
PT2121919E (pt) 2012-05-17
CN101688203A (zh) 2010-03-31
EP2386635A3 (en) 2012-02-08
JP2016187348A (ja) 2016-11-04
ES3008359T3 (en) 2025-03-24
JP2021036901A (ja) 2021-03-11
US20180086814A1 (en) 2018-03-29
JP6426661B2 (ja) 2018-11-21
HRP20120336T1 (hr) 2012-05-31
EP3926045A1 (en) 2021-12-22
CN101688203B (zh) 2013-12-11
CN103641908A (zh) 2014-03-19
GB2447786C (en) 2011-11-09
AU2008228085B2 (en) 2011-12-08
US20100190188A1 (en) 2010-07-29
US20210061882A1 (en) 2021-03-04
US20120270230A1 (en) 2012-10-25
JP7419217B2 (ja) 2024-01-22
US20160052991A1 (en) 2016-02-25
EP2386635A2 (en) 2011-11-16
US8785135B2 (en) 2014-07-22
EP2450445A1 (en) 2012-05-09
ES2381780T3 (es) 2012-05-31
US20240052017A1 (en) 2024-02-15
AU2008228085A1 (en) 2008-09-25
JP2014155502A (ja) 2014-08-28
WO2008114020A2 (en) 2008-09-25
GB2447786A (en) 2008-09-24
GB2456236A (en) 2009-07-15
US20190241644A1 (en) 2019-08-08
GB0901111D0 (en) 2009-03-11
EP3926045B1 (en) 2025-01-01
JP2011224018A (ja) 2011-11-10
CA2681415A1 (en) 2008-09-25
CA2681415C (en) 2020-11-03
DK2121919T3 (da) 2012-05-21
GB2456236B8 (en) 2009-12-09
GB0901095D0 (en) 2009-03-11
JP2010521983A (ja) 2010-07-01
PL2121919T3 (pl) 2012-07-31
GB2456235A (en) 2009-07-15
WO2008114020A9 (en) 2010-03-11
US11673938B2 (en) 2023-06-13
GB0805267D0 (en) 2008-04-30
GB0901110D0 (en) 2009-03-11
EP3926045C0 (en) 2025-01-01
EP2121919B1 (en) 2012-02-08
GB2456237A (en) 2009-07-15
JP4842400B2 (ja) 2011-12-21
GB2456235B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
GB2456237B8 (en) Stable adenosine receptor mutants
WO2009081136A3 (en) Screening
WO2009071914A3 (en) Mutant proteins and methods for producing them
WO2007001636A3 (en) Methods and systems for providing a customized user interface for viewing and editing meta-data
WO2009073664A3 (en) Rating raters
WO2007030729A3 (en) Quick styles for formatting of documents
TW200703969A (en) Systems and methods for beamforming feedback in multi antenna communication systems
WO2010075084A3 (en) User interface tools
WO2007120766A3 (en) Erythropoietin receptor agonists
TW200634624A (en) System, apparatus and method of selecting graphical component types at runtime
WO2010040003A3 (en) Human a2a adenosine receptor crystals and uses thereof
WO2011092504A3 (en) Biomarkers for schizophrenia
WO2007115061A3 (en) Bidding for on-line survey placement
WO2007132359A3 (en) Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist
WO2007101116A3 (en) Glur2 receptor modulators
WO2007047686A3 (en) Brochure creation internet system
WO2006104761A3 (en) Unique sequence hybridization probes (usp)
WO2009045588A3 (en) Determining seawater conductivity for the compensation of electromagnetics-based survey data
WO2006119497A3 (en) Acetylycholine gated ion channel chaperons and methods of using the same
WO2007041219A3 (en) Compositions and methods for il13 biomarkers
MY149586A (en) Pcr screening method
Asano On An Evaluation to Academic Achievement in Basic Structural Mechanics
Ghic USING DIFFERENT ELECTRE METHODS IN MULTICRITERIAL DECISIONS
Kara et al. Corrigendum to “Quantifying SST errors from an OGCM in relation to atmospheric forcing variables”[Ocean Model. 29 (2009) 43–57]
HK1134502A (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20090924 AND 20090930